EVOK Evoke Pharma Inc.

1.52
-0.06  -3%
Previous Close 1.57
Open 1.79
Price To Book 7.24
Market Cap 36,832,509
Shares 24,231,914
Volume 1,374,460
Short Ratio
Av. Daily Volume 328,134
Stock charts supplied by TradingView

NewsSee all news

  1. FDA Accepts Evoke Pharma's NDA Resubmission for Gimoti™

    SOLANA BEACH, Calif., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases,

  2. Evoke Resubmits Gimoti™ New Drug Application to FDA

    SOLANA BEACH, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has

  3. Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement

    SOLANA BEACH, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November

  4. Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price

    SOLANA BEACH, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November

  5. Evoke Pharma Reports Third Quarter 2019 Financial Results

    SOLANA BEACH, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued April 2, 2019. NDA resubmitted with new PDUFA date of June 19, 2020.
Gimoti - EVK-001
Female diabetic gastroparesis

Latest News

  1. FDA Accepts Evoke Pharma's NDA Resubmission for Gimoti™

    SOLANA BEACH, Calif., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases,

  2. Evoke Resubmits Gimoti™ New Drug Application to FDA

    SOLANA BEACH, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has

  3. Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement

    SOLANA BEACH, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November

  4. Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price

    SOLANA BEACH, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November

  5. Evoke Pharma Reports Third Quarter 2019 Financial Results

    SOLANA BEACH, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial

  6. Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™

    SOLANA BEACH, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has